Last reviewed · How we verify
NCT06721130
Role of 18F-FDG PET/CT in the Evaluation of Cavernous Sinus Syndrome: a Pilot Study
trial testing FDG radiotracer in Cavernous Sinus Syndrome in 54 participants. Completed in 30 June 2024.
31 December 2023
Quick facts
| Lead sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 54 |
| Start date | 1 July 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across India |
Drugs / interventions tested
- FDG radiotracer — full drug profile →
Conditions studied
- Cavernous Sinus Syndrome — all drugs for Cavernous Sinus Syndrome →
- Cavernous Sinus Meningioma — all drugs for Cavernous Sinus Meningioma →
- Cavernous Sinus Lesions — all drugs for Cavernous Sinus Lesions →
Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Who can join
18 and older, any sex, with Cavernous Sinus Syndrome or Cavernous Sinus Meningioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cavernous sinus syndrome (CSS) can be caused by a wide range of inflammatory, malignant, benign, vascular and miscellaneous disorders. Even after modern advances, reaching the final etiological diagnosis remains a challenge in CSS. This study is planned to determine the role and incremental value of 18F-FDG PET/CT in characterising different cavernous sinus pathologies based on their metabolic activity and detecting extracranial involvement.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06721130
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Post Graduate Institute of Medical Education and Research, Chandigarh trials
Trials by the same sponsor.
- NCT07322237 — DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis · Phase 4 · recruiting
- NCT07436988 — Affordable Made-in-India Microspheres for Liver Cancer Therapy · Phase 1 · not yet recruiting
- NCT07286643 — Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis · NA · recruiting
- NCT07280390 — Microplastics, Cirrhosis and Portal Hypertension · not yet recruiting
- NCT07182877 — Comparison of Dwell Time of Open Versus Closed Type Peripheral Intravenous Cannula · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06721130 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Post Graduate Institute of Medical Education and Research, Chandigarh
- Last refreshed: 6 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06721130.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing